0727 GMT - The market is pricing in tariff risks for pharma stocks despite drugs currently being exempt from U.S. President Trump's potential tariffs, Berenberg analysts say in a note. Uncertainty from tariffs and substantial layoffs at the Food and Drug Administration and other U.S. health departments have dragged pharma share prices lower, they say. Berenberg reiterate its buy ratings on U.K. drugmaker AstraZeneca and French pharma giant Sanofi due to share-price erosion and lower exposure to the U.S. market. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 03:27 ET (07:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。